Figure 1.

The SIX1 gene expression levels both in vivo and using bioinformatic analysis in different types of cancer.(A) Analysis of the expression levels of SIX1 in cancer cDNA arrays representing tissues from 3 non-malignant and 9 tumor samples from 8 different types of cancer. Compared with the control tissue, the expression levels of SIX1 in the liver, colon, breast, ovary, kidney, lung, and prostate tumor tissues were markedly upregulated, while they were slightly downregulated in thyroid cancer. mRNA expression levels were quantified using the 2^−ΔΔCq method. (B) mRNA transcription levels of SIX1 in colon, liver, and breast cancers depending on the pathological stages using an Expression Project for Oncology (expO) dataset. SIX1 expression was significantly upregulated in pathological stage 3 compared to pathological stage 1 in the liver and colon cancer, and also SIX1 high expression was detected in stage 4 compared to stage 1 in all 3 types of cancer (^* P < .05). (C) SIX1 expression levels in tumor tissues were compared with normal tissues in 3 different grades of hepatocellular carcinoma. SIX1 expression levels in grade 1 (n = 6) and grade 3 (n = 20) were significantly different in the tumor tissues compared with the normal tissues. In contrast, no significant differences were observed in grade 2 tissues (n = 12). NAT, non-associated tissue; SIX1, Sine oculis homeoprotein 1. ^* P < .05, unpaired Student’s t-test. Magnification, ×40; scale bar, 200 μm.